

PÃ¡l Czobor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5440335/publications.pdf>

Version: 2024-02-01

148
papers

10,037
citations

50276

46
h-index

37204

96
g-index

149
all docs

149
docs citations

149
times ranked

9196
citing authors

#	ARTICLE	IF	CITATIONS
1	A Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes. <i>American Journal of Psychiatry</i> , 2011, 168, 472-485.	7.2	1,437
2	Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. <i>British Journal of Psychiatry</i> , 2009, 194, 204-211.	2.8	1,200
3	Neurocognitive Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol in Patients With Chronic Schizophrenia or Schizoaffective Disorder. <i>American Journal of Psychiatry</i> , 2002, 159, 1018-1028.	7.2	493
4	Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics. <i>American Journal of Psychiatry</i> , 2003, 160, 290-296.	7.2	450
5	Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder. <i>American Journal of Psychiatry</i> , 2002, 159, 255-262.	7.2	377
6	Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia. <i>Biological Psychiatry</i> , 2002, 52, 701-707.	1.3	304
7	Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. <i>Lancet</i> , The, 2017, 389, 1103-1113.	13.7	249
8	Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia. <i>Psychiatric Services</i> , 2001, 52, 1510-1514.	2.0	177
9	Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 225-228.	1.4	160
10	Prolactin Levels in Schizophrenia and Schizoaffective Disorder Patients Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 57-61.	2.2	151
11	Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 244-251.	1.4	149
12	Processing of unattended facial emotions: A visual mismatch negativity study. <i>NeuroImage</i> , 2012, 59, 3042-3049.	4.2	149
13	Gender Differences in Violent Behaviors: Relationship to Clinical Symptoms and Psychosocial Factors. <i>American Journal of Psychiatry</i> , 2004, 161, 459-465.	7.2	141
14	The Multidimensional Scale of Independent Functioning: A New Instrument for Measuring Functional Disability in Psychiatric Populations. <i>Schizophrenia Bulletin</i> , 2003, 29, 153-167.	4.3	130
15	Psychopathy and Violent Behavior Among Patients With Schizophrenia or Schizoaffective Disorder. <i>Psychiatric Services</i> , 1999, 50, 787-792.	2.0	127
16	Characteristics of Assaultive Behavior Among Psychiatric Inpatients. <i>Psychiatric Services</i> , 2003, 54, 1012-1016.	2.0	121
17	Effect of Risperidone on Hostility in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 1995, 15, 243-249.	1.4	119
18	The generalizability of the Buss&Perry Aggression Questionnaire. <i>International Journal of Methods in Psychiatric Research</i> , 2007, 16, 124-136.	2.1	114

#	ARTICLE	IF	CITATIONS
19	History of violent behaviour and schizophrenia in different cultures. <i>British Journal of Psychiatry</i> , 1997, 171, 9-14.	2.8	105
20	Preclinical and Clinical Pharmacology of DOVâ€f216,303, a â€œTripleâ€•Reuptake Inhibitor. <i>CNS Neuroscience & Therapeutics</i> , 2006, 12, 123-134.	4.0	97
21	The InterSePT scale for suicidal thinking reliability and validity. <i>Schizophrenia Research</i> , 2003, 63, 161-170.	2.0	94
22	The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. <i>Neuroscience Letters</i> , 2005, 379, 81-89.	2.1	93
23	Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. <i>European Neuropsychopharmacology</i> , 2015, 25, 1158-1166.	0.7	84
24	Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder. <i>Psychiatry Research - Neuroimaging</i> , 2005, 140, 133-145.	1.8	79
25	HIV seroprevalence and risk behaviors in psychiatric inpatients. <i>Psychiatry Research</i> , 1991, 39, 109-114.	3.3	78
26	Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. <i>Journal of Psychiatric Research</i> , 2012, 46, 64-71.	3.1	78
27	Clinical and Neurocognitive Effects of Clozapine and Risperidone in Treatment-Refractory Schizophrenic Patients. <i>Journal of Clinical Psychiatry</i> , 1998, 59, 521-527.	2.2	77
28	Regional Grey Matter Structure Differences between Transsexuals and Healthy Controlsâ€”A Voxel Based Morphometry Study. <i>PLoS ONE</i> , 2013, 8, e83947.	2.5	73
29	Dysfunctional core beliefs, perceived parenting behavior and psychopathology in gender identity disorder: A comparison of male-to-female, female-to-male transsexual and nontranssexual control subjects. <i>Journal of Behavior Therapy and Experimental Psychiatry</i> , 2011, 42, 38-45.	1.2	71
30	Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. <i>Journal of Psychiatric Research</i> , 2005, 39, 109-115.	3.1	65
31	The measurement of subjective experience in schizophrenia: The subjective deficit syndrome scale. <i>Comprehensive Psychiatry</i> , 1990, 31, 216-226.	3.1	63
32	Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. <i>Schizophrenia Research</i> , 2009, 110, 95-102.	2.0	62
33	Violence in psychiatric patients: The role of psychosis, frontal lobe impairment, and ward turmoil. <i>Comprehensive Psychiatry</i> , 1997, 38, 230-236.	3.1	61
34	Suggestive association between the C825T polymorphism of the G-protein Î²3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. <i>European Neuropsychopharmacology</i> , 2005, 15, 525-531.	0.7	59
35	Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: To switch or to combine? A nationwide study in Hungary. <i>Schizophrenia Research</i> , 2014, 152, 246-254.	2.0	59
36	Effects of Atypical Antipsychotics on the Syndromal Profile in Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 551-556.	2.2	59

#	ARTICLE	IF	CITATIONS
37	Drug Effect Prediction by Polypharmacology-Based Interaction Profiling. <i>Journal of Chemical Information and Modeling</i> , 2012, 52, 134-145.	5.4	57
38	Facial Expression Recognition in Depressed Subjects. <i>Journal of Nervous and Mental Disease</i> , 2009, 197, 98-103.	1.0	56
39	Atypical Antipsychotics, Neurocognitive Deficits, and Aggression in Schizophrenic Patients. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 485-493.	1.4	55
40	Pharmacological treatment of negative symptoms in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 567-578.	3.2	55
41	Basic neuropsychological dimensions in schizophrenia. <i>Schizophrenia Research</i> , 2003, 65, 105-116.	2.0	54
42	The Secrets of a Successful Clinical Trial: Compliance, Compliance, and Compliance. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2011, 11, 107-110.	3.4	54
43	Placebo or Active Control Trials of Antipsychotic Drugs?. <i>Archives of General Psychiatry</i> , 2003, 60, 458.	12.3	52
44	Pretreatment EEG predicts short-term response to haloperidol treatment. <i>Biological Psychiatry</i> , 1991, 30, 927-942.	1.3	51
45	DOV 216,303, a "Triple" Reuptake Inhibitor: Safety, Tolerability, and Pharmacokinetic Profile. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 1360-1367.	2.0	50
46	Emotion-Related Visual Mismatch Responses in Schizophrenia: Impairments and Correlations with Emotion Recognition. <i>PLoS ONE</i> , 2013, 8, e75444.	2.5	50
47	Family and case-control association study of the tumor necrosis factor-alpha (TNF- α) gene with schizophrenia and response to antipsychotic medication. <i>Psychopharmacology</i> , 2006, 188, 171-182.	3.1	48
48	Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SÓHO). <i>European Psychiatry</i> , 2005, 20, 403-408.	0.2	47
49	How do different diagnostic criteria, age and gender affect the prevalence of attention deficit hyperactivity disorder in adults? An epidemiological study in a Hungarian community sample. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 287-296.	3.2	46
50	Cholesterol and cognition in schizophrenia: A double-blind study of patients randomized to clozapine, olanzapine and haloperidol. <i>Schizophrenia Research</i> , 2011, 130, 27-33.	2.0	45
51	Multivariate patterns of EEG microstate parameters and their role in the discrimination of patients with schizophrenia from healthy controls. <i>Psychiatry Research</i> , 2020, 288, 112938.	3.3	45
52	Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. <i>International Clinical Psychopharmacology</i> , 2007, 22, 356-362.	1.7	43
53	Acute Mania: Haloperidol Dose and Augmentation With Lithium or Lorazepam. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 500-505.	1.4	42
54	Pharmacoeconomics of Clozapine in 202 Inpatients with Schizophrenia. <i>Annals of Pharmacotherapy</i> , 1993, 27, 1262-1269.	1.9	42

#	ARTICLE	IF	CITATIONS
55	Symptomatic Overlap of Cocaine Intoxication and Acute Schizophrenia at Emergency Presentation. <i>Schizophrenia Bulletin</i> , 1999, 25, 387-394.	4.3	41
56	Course of Patients With Histories of Aggression and Crime After Discharge From a Cognitive-Behavioral Program. <i>Psychiatric Services</i> , 2004, 55, 654-659.	2.0	41
57	Eating Disorder Behavior and Early Maladaptive Schemas in Subgroups of Eating Disorders. <i>Journal of Nervous and Mental Disease</i> , 2010, 198, 425-431.	1.0	41
58	Alterations in resting-state gamma activity in patients with schizophrenia: a high-density EEG study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 429-437.	3.2	41
59	Relationship between the brief psychiatric rating scale and the scale for the assessment of negative symptoms: A study of their correlation and redundancy. <i>Psychiatry Research</i> , 1991, 36, 129-139.	3.3	40
60	Depression and Impulsivity as Pathways to Violence: Implications for Antiaggressive Treatment. <i>Schizophrenia Bulletin</i> , 2014, 40, 886-894.	4.3	40
61	Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes. <i>Psychiatry Research</i> , 1997, 71, 19-26.	3.3	39
62	General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 107-115.	3.2	39
63	Neuroleptics in Acute Mania: A Pharmacoepidemiologic Study. <i>Annals of Pharmacotherapy</i> , 1996, 30, 1396-1398.	1.9	38
64	Aggression and Quantitative MRI Measures of Caudate in Patients With Chronic Schizophrenia or Schizoaffective Disorder. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2006, 18, 509-515.	1.8	38
65	Assessment of Risk Behaviors for HIV Infection Among Psychiatric Inpatients. <i>Psychiatric Services</i> , 1992, 43, 482-485.	2.0	36
66	Early maladaptive schemas and body mass index in subgroups of eating disorders: a differential association. <i>Comprehensive Psychiatry</i> , 2007, 48, 199-204.	3.1	35
67	Efficacy of Ziprasidone Against Hostility in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 638-642.	2.2	35
68	Post-Error Slowing in Patients With ADHD. <i>Journal of Attention Disorders</i> , 2016, 20, 1004-1016.	2.6	34
69	Disturbances in Response Inhibition and Emotional Processing as Potential Pathways to Violence in Schizophrenia: A High-Density Event-Related Potential Study. <i>Schizophrenia Bulletin</i> , 2016, 42, 963-974.	4.3	34
70	Efficacy of Aripiprazole Against Hostility in Schizophrenia and Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1362-1366.	2.2	34
71	Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. <i>CNS Spectrums</i> , 2014, 19, 374-381.	1.2	33
72	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). <i>Journal of Affective Disorders</i> , 2022, 299, 367-376.	4.1	33

#	ARTICLE	IF	CITATIONS
73	Clinical Symptoms, Neurological Impairment, and Prediction of Violence in Psychiatric Inpatients. <i>Psychiatric Services</i> , 1994, 45, 700-705.	2.0	32
74	Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve. <i>Psychiatry Research</i> , 1992, 42, 129-144.	3.3	31
75	Gender differences in trait aggression in young adults with drug and alcohol dependence compared to the general population. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1333-1340.	4.8	31
76	Executive Function Predicts Response to Antiaggression Treatment in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 74-80.	2.2	31
77	Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: A nationwide study in Hungary. <i>European Neuropsychopharmacology</i> , 2013, 23, 1383-1390.	0.7	29
78	Substance Use in Roma and Non-Roma Adolescents. <i>Journal of Nervous and Mental Disease</i> , 2010, 198, 432-436.	1.0	27
79	A Multicenter, Placeboâ€Controlled, Doubleâ€Blind, Randomized Study of Efficacy and Safety of Ocinaplon (DOV 273,547) in Generalized Anxiety Disorder. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 63-75.	3.9	26
80	Dimensions of the brief psychiatric rating scale: An examination of stability during haloperidol treatment. <i>Comprehensive Psychiatry</i> , 1996, 37, 205-215.	3.1	25
81	Neuroanatomical Abnormalities in Violent Individuals with and without a Diagnosis of Schizophrenia. <i>PLoS ONE</i> , 2016, 11, e0168100.	2.5	25
82	High-Dose Treatment With Haloperidol: The Effect of Dose Reduction. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 252-256.	1.4	25
83	Prolactin response to d-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. <i>Schizophrenia Research</i> , 1998, 30, 91-99.	2.0	24
84	Adverse reactions to duloxetine in depression. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 839-850.	2.4	24
85	Early sensoryâ€perceptual processing deficits for affectively valenced inputs are more pronounced in schizophrenia patients with a history of violence than in their non-violent peers. <i>Social Cognitive and Affective Neuroscience</i> , 2013, 8, 678-687.	3.0	23
86	The Importance of Conduct Disorder in the Treatment of Violence in Schizophrenia: Efficacy of Clozapine Compared With Olanzapine and Haloperidol. <i>American Journal of Psychiatry</i> , 2021, 178, 266-274.	7.2	23
87	Long-Term High-Dose Neuroleptic Treatment: Who Gets It and Why?. <i>Psychiatric Services</i> , 1993, 44, 640-644.	2.0	22
88	Trait aggression, depression and suicidal behavior in drug dependent patients with and without ADHD symptoms. <i>Psychiatry Research</i> , 2012, 200, 719-723.	3.3	21
89	Fearful face recognition in schizophrenia: An electrophysiological study. <i>Schizophrenia Research</i> , 2013, 149, 135-140.	2.0	21
90	A new rating scale for negative symptoms: The Motor-Affective-Social Scale. <i>Psychiatry Research</i> , 2008, 160, 346-355.	3.3	20

#	ARTICLE	IF	CITATIONS
91	Functional impairment in adults positively screened for attention-deficit hyperactivity disorder: The role of symptom presentation and executive functioning. <i>Comprehensive Psychiatry</i> , 2013, 54, 974-981.	3.1	20
92	Physical Aggression and Concurrent Alcohol and Tobacco Use Among Adolescents. <i>International Journal of Mental Health and Addiction</i> , 2017, 15, 90-99.	7.4	20
93	Suicidality and trait aggression related to childhood victimization in patients with alcoholism. <i>Psychiatry Research</i> , 2009, 165, 103-110.	3.3	19
94	Event-related theta synchronization predicts deficit in facial affect recognition in schizophrenia.. <i>Journal of Abnormal Psychology</i> , 2014, 123, 178-189.	1.9	19
95	ADHD: a hidden comorbidity in adult psychiatric patients. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2019, 11, 83-89.	1.7	19
96	Psychosocial Risk Factors Associated With Suicide Attempts and Violence Among Psychiatric Inpatients. <i>Psychiatric Services</i> , 2004, 55, 1414-1419.	2.0	18
97	Associating functional recovery with neurocognitive profiles identified using partially ordered classification models. <i>Schizophrenia Research</i> , 2006, 85, 40-48.	2.0	18
98	Basic emotions and psychological distress: association between recognition of facial expressions and Symptom Checklist-90 subscales. <i>Comprehensive Psychiatry</i> , 2008, 49, 177-183.	3.1	18
99	The denial of aggression in violent patients with schizophrenia. <i>Schizophrenia Research</i> , 2012, 141, 228-233.	2.0	18
100	Experimental Confirmation of New Drug-Target Interactions Predicted by Drug Profile Matching. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8377-8388.	6.4	18
101	Distinctive profiles of traits predisposing to violence in schizophrenia and in the general population. <i>Schizophrenia Research</i> , 2018, 202, 267-273.	2.0	18
102	Decreased resting gamma activity in adult attention deficit/hyperactivity disorder. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 691-702.	2.6	18
103	Subject Selection for the Placebo- and Comparator-Controlled Trials of Neuroleptics in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 240-245.	1.4	18
104	Efficacy of typical and atypical antipsychotic medication on hostility in patients with psychosis-spectrum disorders: a review and meta-analysis. <i>Neuropsychopharmacology</i> , 2018, 43, 2340-2349.	5.4	17
105	Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. <i>Psychiatry Research</i> , 1998, 81, 51-55.	3.3	16
106	Aggression Levels in Treatment Seeking Inpatients With Alcohol-Related Problems Compared to Levels in the General Population in Hungary. <i>Journal of Nervous and Mental Disease</i> , 2007, 195, 669-672.	1.0	16
107	Contribution of 2D and 3D Structural Features of Drug Molecules in the Prediction of Drug Profile Matching. <i>Journal of Chemical Information and Modeling</i> , 2012, 52, 1733-1744.	5.4	16
108	Pharmacological treatment of adult ADHD. <i>Current Opinion in Psychiatry</i> , 2012, 25, 529-534.	6.3	15

#	ARTICLE	IF	CITATIONS
109	The predictive validity of the Leonhardean classification of endogenous psychoses. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 324-334.	3.2	14
110	Virtual Affinity Fingerprints for Target Fishing: A New Application of Drug Profile Matching. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 103-113.	5.4	14
111	Insight and Hostility as Predictors and Correlates of Nonadherence in the European First Episode Schizophrenia Trial. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 258-261.	1.4	14
112	Pretreatment plasma HVA and haloperidol response in acute mania. <i>Journal of Affective Disorders</i> , 2000, 59, 55-59.	4.1	13
113	Proneness to aggression and its inhibition in schizophrenia: Interconnections between personality traits, cognitive function and emotional processing. <i>Schizophrenia Research</i> , 2017, 184, 82-87.	2.0	13
114	A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: Are the results consistent with the findings of randomized controlled trials?. <i>Translational Psychiatry</i> , 2021, 11, 510.	4.8	13
115	Methylphenidate Treatment and Dyskinesia in Children with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 133-138.	1.3	12
116	Electrophysiological indices of aberrant error-processing in adults with ADHD: a new region of interest. <i>Brain Imaging and Behavior</i> , 2017, 11, 1616-1628.	2.1	12
117	Neural Correlates of Error Monitoring in Adult Attention Deficit Hyperactivity Disorder After Failed Inhibition in an Emotional Go/No-Go Task. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2017, 29, 326-333.	1.8	12
118	Emotion antecedents in schizophrenia. <i>Psychiatry Research</i> , 2009, 169, 43-50.	3.3	11
119	Psychometric Characteristics of the Drug Use Disorders Identification Test (DUDIT) and the Drug Use Disorders Identification Test-Extended (DUDIT-E) Among Young Drug Users in Hungary. <i>International Journal of Behavioral Medicine</i> , 2014, 21, 547-555.	1.7	11
120	Aberrant response inhibition and task switching in psychopathic individuals. <i>Psychiatry Research</i> , 2015, 229, 1017-1023.	3.3	11
121	Impaired early information processing in adult ADHD: a high-density ERP study. <i>BMC Psychiatry</i> , 2020, 20, 292.	2.6	11
122	Quantitative Craniofacial Anomalies in a Racially Mixed Schizophrenia Sample. <i>Biological Psychiatry</i> , 2006, 59, 349-353.	1.3	10
123	Heavy drinking as a differential predictor of physical aggression in clinical and general populations. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 668-672.	4.8	10
124	Psychopathological Symptom Dimensions in Patients with Gastrointestinal Disorders. <i>Journal of Clinical Psychology in Medical Settings</i> , 2010, 17, 378-386.	1.4	10
125	Attention deficit hyperactivity disorder: Last in, first out - delayed brain maturation with an accelerated decline?. <i>European Neuropsychopharmacology</i> , 2020, 34, 65-75.	0.7	9
126	Effects of haloperidol treatment on prolactin response to D -fenfluramine challenge in acute schizophrenia. <i>Psychopharmacology</i> , 1999, 141, 322-325.	3.1	8

#	ARTICLE	IF	CITATIONS
127	Identification of a naturally occurring 21bp deletion in alpha2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. <i>Pharmacological Research</i> , 2005, 51, 381-384.	7.1	8
128	Altered response-preparation in patients with adult ADHD: A high-density ERP study. <i>Psychiatry Research - Neuroimaging</i> , 2016, 249, 57-66.	1.8	8
129	Suicidal ideation in adult ADHD: Gender difference with a specific psychopathological profile. <i>Comprehensive Psychiatry</i> , 2018, 85, 23-29.	3.1	8
130	The European Adolescent Assessment Dialogue (EuroADAD): A Psychometric Evaluation. <i>European Addiction Research</i> , 2011, 17, 302-315.	2.4	7
131	Beyond principal component analysis: Canonical component analysis for data reduction in classification of EPs. <i>International Journal of Bio-medical Computing</i> , 1984, 15, 93-111.	0.5	5
132	Catechol-O-methyltransferase and Monoamine Oxidase-A Polymorphisms and Treatment Response to Typical and Atypical Neuroleptics. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 338-340.	1.4	5
133	Validity of Reliability. <i>Journal of Nervous and Mental Disease</i> , 2007, 195, 606-613.	1.0	5
134	A Prospective Longitudinal Study of Cholesterol and Aggression in Patients Randomized to Clozapine, Olanzapine, and Haloperidol. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 198-200.	1.4	5
135	Predictors of suicide attempts after violent offences in schizophrenia spectrum disorders. <i>Psychiatry Research</i> , 2015, 230, 728-731.	3.3	4
136	What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial. <i>Frontiers in Psychiatry</i> , 2022, 13, 816339.	2.6	4
137	Does the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication?. <i>Psychiatry Research</i> , 1994, 52, 107-114.	3.3	3
138	Haloperidol Blood Levels in Acute Mania With Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 445-447.	1.4	3
139	Atypical resting-state gamma band trajectory in adult attention deficit/hyperactivity disorder. <i>Journal of Neural Transmission</i> , 2021, 128, 1239-1248.	2.8	3
140	Comparative Effectiveness of Second Generation Long-acting Injectable Antipsychotics Based on Nationwide Database Research in Hungary: An Update. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	1.7	3
141	Separate pathways to violent behavior in schizophrenia and in the general population. <i>Journal of Psychiatric Research</i> , 2022, 151, 235-241.	3.1	3
142	Placebo Response in Trials of Negative Symptoms in Schizophrenia: A Critical Reassessment of the Evidence. <i>Schizophrenia Bulletin</i> , 2022, 48, 1228-1240.	4.3	2
143	A study of periodicity and structure of EEG complexes in a case of SSPE. <i>Electroencephalography and Clinical Neurophysiology</i> , 1980, 50, 11-18.	0.3	1
144	Sphincter of Oddi dysfunction: Does Psychosocial Distress Play a Role?. <i>Journal of Clinical Psychology in Medical Settings</i> , 2007, 14, 138-144.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Understanding the Risk of Treatment Failure After Discontinuation of Long-Term Antipsychotic Treatment. American Journal of Psychiatry, 2018, 175, 908-909.	7.2	0
146	Dr. Bilder and Colleagues Reply. American Journal of Psychiatry, 2002, 159, 2118-a-2119.	7.2	0
147	Dr. Volavka and Colleagues Reply. American Journal of Psychiatry, 2003, 160, 592-593.	7.2	0
148	The Options and Limitations of the Brain Fingerprinting Lie Detection Method in the Criminal Proceeding. Magyar Rendőszet, 2018, 18, 43-56.	0.1	0